Immuneering: Funding, Investors & Team (Sep 2026)
Immuneering is a biopharmaceutical company that uses its expertise in translational bioinformatics to enhance outcomes for patients with cancer and neurological disorders. With over ten years of experience, the company applies its knowledge to all aspects of drug development, gaining valuable insights into how drugs work and how patients respond to treatment.
Immuneering has raised $62.2M across 2 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immuneering Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Immuneering Funding Rounds
Immuneering raised $37.2M in an undisclosed round announced in Jan 2021.
4.6 years later, an undisclosed round of $25.0M was announced in Aug 2025.
Immuneering Founders and Leadership Team
Contact details for the Immuneering team: 1 of 1 has an email address on file.
Start 14-day free trial →Immuneering Funding Compared to Other Biotechnology Startups
Immuneering's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immuneering in Biotechnology and Cambridge
Companies Similar to Immuneering
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Immuneering Funding FAQs
What does Immuneering do?
Immuneering is a biopharmaceutical company that uses its expertise in translational bioinformatics to enhance outcomes for patients with cancer and neurological disorders. With over ten years of experience, the company applies its knowledge to all aspects of drug development, gaining valuable insights into how drugs work and how patients respond to treatment.
How much funding has Immuneering raised?
Immuneering has raised $62.2M across 2 rounds on record. The most recent is an undisclosed round of $25.0M announced in Aug 2025.
When did Immuneering last raise funding?
Immuneering's most recent funding round on record is an undisclosed round of $25.0M, announced in Aug 2025.
Who founded Immuneering?
FundedIQ lists Ben Zeskind (Founder) at Immuneering.
Where is Immuneering headquartered?
Immuneering is based in Cambridge, Massachusetts, United States.
How many employees does Immuneering have?
Immuneering is in the 51-100 employee band.
How does Immuneering's funding compare to other Biotechnology startups?
Immuneering's latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Immuneering Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immuneering is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.